LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Aandelen Lijst・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

111.36 -0.23

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

110.2

Max

114.12

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.3M -53M
Verkoop	2.8M 51M
EPS	-0.82
Winstmarge	-103.131
Werknemers	283
EBITDA	-7.6M -48M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+24.07% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-45M 7.5B
Vorige openingsprijs	111.59
Vorige sluitingsprijs	111.36

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

60 / 65.58 Steun & Weerstand

Rhythm Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 dec 2025, 17:29 UTC

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 dec 2025, 16:47 UTC

Belangrijke Marktbewegers

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 dec 2025, 16:10 UTC

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19 dec 2025, 22:33 UTC

Winsten

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 dec 2025, 22:19 UTC

Winsten

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 dec 2025, 21:48 UTC

Acquisities, Fusies, Overnames

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dec 2025, 21:44 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dec 2025, 21:38 UTC

Winsten

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 dec 2025, 21:00 UTC

Marktinformatie

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 dec 2025, 20:23 UTC

Marktinformatie

Oil Futures End Down Week on Up Note -- Market Talk

19 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 dec 2025, 18:38 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 dec 2025, 18:00 UTC

Marktinformatie

Winsten

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 dec 2025, 17:41 UTC

Winsten

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dec 2025, 17:24 UTC

Marktinformatie

Winsten

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 dec 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

19 dec 2025, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

19 dec 2025, 16:29 UTC

Winsten

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 dec 2025, 16:20 UTC

Acquisities, Fusies, Overnames

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 dec 2025, 16:19 UTC

Acquisities, Fusies, Overnames

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 dec 2025, 16:18 UTC

Acquisities, Fusies, Overnames

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 dec 2025, 16:16 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 dec 2025, 16:16 UTC

Marktinformatie

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 dec 2025, 16:05 UTC

Acquisities, Fusies, Overnames

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dec 2025, 16:04 UTC

Acquisities, Fusies, Overnames

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dec 2025, 15:37 UTC

Marktinformatie

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19 dec 2025, 15:21 UTC

Marktinformatie

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19 dec 2025, 15:09 UTC

Marktinformatie

Gold Flat But Set for Weekly Gains -- Market Talk

19 dec 2025, 15:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 dec 2025, 15:09 UTC

Winsten

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Peer Vergelijking

Prijswijziging

Rhythm Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

24.07% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 138.62 USD 24.07%

Hoogste 167 USD

Laagste 110 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rhythm Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Rhythm Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60 / 65.58Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.